Cell Genesys reports long-term survival data in Phase II trial of GVAX.
D019496:Cancer Vaccines / Q000276:immunology / Q000627:therapeutic use*; D017322:Clinical Trials, Phase II as Topic; D004306:Dose-Response Relationship, Immunologic; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000276:immunology / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000401:mortality; D015996:Survival Rate; D017741:Survivors
D019496:Cancer Vaccines; D016178:Granulocyte-Macrophage Colony-Stimulating Factor